Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical, Inc. (VANI)
Company Research
Source: Business Wire
NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administrationStudy represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Company’s proprietary NanoPortal™ drug implant technology.“Transitioning to a clinical stage biopharmaceutical company is a major milestone for our company and allows us to determine if the very encouraging results from
Show less
Read more
Impact Snapshot
Event Time:
VANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VANI alerts
High impacting Vivani Medical, Inc. news events
Weekly update
A roundup of the hottest topics
VANI
News
- Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia [Yahoo! Finance]Yahoo! Finance
- EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia [Yahoo! Finance]Yahoo! Finance
- Halia CEO David Bearss, Ph.D., to Present and Participate in Panel Discussion at Obesity Innovation Therapeutics Summit 2024 [Yahoo! Finance]Yahoo! Finance
- Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast [Yahoo! Finance]Yahoo! Finance
- Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West CoastBusiness Wire
VANI
Analyst Actions
- 11/7/24 - HC Wainwright
VANI
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- VANI's page on the SEC website